{"filings":[{"id":1231716,"accession_number":"0001437749-26-021504","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2026-06-24T11:45:56+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Picard Medical CEO Patrick Schnegelsberg steps down; Chairman Richard Fang named interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patrick NJ Schnegelsberg resigned as CEO and board member effective June 18, 2026; departure not related to any disagreement.","Board appointed Richard Fang, Ph.D., current Chairman, as Interim CEO effective June 18, 2026; he will serve until permanent successor found.","Dr. Fang previously served as CEO from 2021 to 2023; founded Reach Surgical and has over 20 years med-tech experience.","As Interim CEO, Dr. Fang will receive an annual salary of $400,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":787198,"accession_number":"0001437749-26-019099","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2026-06-02T10:29:54+00:00","items":["5.02"],"status":"ready","headline":"Picard Medical terminates CFO Bernard Skaggs; appoints Georgina Smith as CAO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bernard Skaggs terminated as CFO, effective June 1, 2026.","Georgina Smith, 54, appointed Chief Accounting Officer, effective same date.","Smith previously served as Controller of SynCardia Systems, a Picard subsidiary.","Smith holds an MBA and CPA; no related party transactions in her appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":731197,"accession_number":"0001829126-26-005779","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2026-05-29T11:05:27+00:00","items":["7.01","9.01"],"status":"ready","headline":"Picard Medical Q1 revenue up 85%, gross margin 24%; NYSE listing notice received","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q1 2026 revenue $1.2M (+85% YoY); gross profit margin 24% vs. -58% in Q1 2025.","2025 total revenue $4.9M (+12.5%); IPO raised $17.4M net; year-end cash $11.5M.","Repaid $7.4M senior debt in Q1; post-quarter public offering raised $5.0M gross.","Next-gen Emperor TAH second-gen animal testing completed May 2026; FDA submission target 2028.","NYSE American notified of stockholders' equity deficiency; compliance plan due June 7, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":582205,"accession_number":"0001829126-26-005568","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2026-05-21T20:15:19+00:00","items":["2.02","3.01","7.01","9.01"],"status":"ready","headline":"Picard Medical Q1 revenue up 85% to $1.2M; reports $1.4M negative equity, NYSE listing notices","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Revenue $1.2M (+85% YoY); gross profit $0.3M (24% margin) vs gross loss of $0.4M in Q1 2025.","Net loss $7.6M including non-cash debt settlement and fair value charges.","Reduced senior secured note balance from ~$10.8M to ~$1.3M via cash, equity, and cashless transactions.","Subsequent public offering raised $5.0M gross; warrant exchange replaced 7M high-price warrants with 10M at $0.35.","Received NYSE American non-compliance notices for equity standards (deficit $1.4M); must submit plan by June 7, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":15201,"accession_number":"0001829126-26-004960","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2026-05-11T21:08:14+00:00","items":["1.01","3.01","9.01"],"status":"ready","headline":"Picard Medical raises $5M in public offering, receives NYSE American delisting notice for low equity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $5.0M from sale of ~16.7M shares (or pre-funded warrants) and Series A/B warrants at $0.30 per unit.","Proceeds used for working capital and debt repayment; offering closed May 6, 2026.","NYSE American notified stockholders' equity of $3.8M as of Dec 31, 2025 is below $4M threshold; PMI must submit compliance plan by June 7, 2026.","Regain compliance deadline Nov 8, 2027; stock continues trading with '.BC' indicator.","Company directors and officers subject to 30-day lock-up; 60-day company restriction on further issuance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97343,"accession_number":"0001829126-26-004529","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Picard Medical prices $5M offering, exchanges high-price warrants for new $0.35 warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$5M from selling 16.67M shares and common warrants at $0.30/unit.","Existing warrants for 7.01M shares at $2.675 exchanged for new warrants for 10M shares at $0.35.","New warrants eliminate forced exercise and anti-dilution provisions present in old warrants.","Net proceeds for working capital and payoff of senior secured note and working capital loans.","Offering expected to close May 6, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97342,"accession_number":"0001829126-26-003733","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Picard Medical Q1 preliminary revenue up 79.9% to $1.1M; driven by STAH sales","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited revenue of $1.1M for Q1 2026 vs $0.6M in Q1 2025, a 79.9% increase.","Growth driven by higher SynCardia Total Artificial Heart (STAH) sales, favorable U.S. reimbursement, and pricing adjustments on driver rentals.","CEO cites progress in commercial initiatives and increased STAH utilization as bridge-to-transplant.","Full Q1 results to be filed in Form 10-Q on or before May 15, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97341,"accession_number":"0001829126-26-003451","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["1.01","2.03","3.02","3.03","9.01"],"status":"ready","headline":"Picard Medical closes $500K convertible note with Quick Capital; 80K origination shares issued","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued convertible note with $555,556 principal; funded $500,000 after $55,556 OID; cash received $490,000 after expenses.","Note bears 12% one-time interest ($66,667); matures 9 months; repayable in 6 monthly installments of $103,704 starting July 1, 2026.","Issued 80,128 origination shares (15% of note value) as additional consideration.","Upon default, note accelerates at 150% and convertible at 75% of lowest prior 10-day trading price, subject to 4.99% ownership limit.","Until note is satisfied, Company cannot pay dividends or make distributions without Buyer's consent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112021,"accession_number":"0001829126-26-002794","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Picard Medical FY2025 revenue $4.94M (+12.5% YoY); U.S. rev +33.5%","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Revenue $4.94M (+12.5% YoY); U.S. revenue +33.5% to 88.25% of total.","Net loss ~$27M (incl. $14.5M non-cash); cash burn $15.67M; IPO raised $35.55M.","Emperor TAH in preclinical; FDA Breakthrough designation possible in 2026; 2028 clinical study target.","Manufacturing: valve assembly in-house, driver transfer to China, second source qualification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112020,"accession_number":"0001829126-26-002663","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Picard Medical FY2025 revenue up 12.5% to $4.9M, net loss widens to $27.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.94M (+12.5% YoY); product revenue $4.75M, 96% of total.","Gross margin negative 4.1% vs -2.6% in 2024; gross loss $(0.2)M.","Operating loss $(13.3)M, slightly improved from $(13.7)M; net loss $(27.0)M vs $(21.1)M.","Cash & equivalents $11.5M at year-end vs $0.1M in 2024; raised $17.4M net from equity and $9.7M net from debt in 2025.","Company expects to continue investing; additional capital needed to support operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112019,"accession_number":"0001829126-26-002557","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Picard Medical to present preclinical data on Emperor Total Artificial Heart at ACC.26","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Poster presentation on March 29, 2026, featuring early preclinical data on fully implantable Emperor Total Artificial Heart.","System designed as autoregulating electromechanical artificial heart building on SynCardia platform.","SynCardia exhibiting at booth #2554 throughout ACC.26 conference in New Orleans.","No financial results, guidance changes, or regulatory milestones announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112018,"accession_number":"0001829126-26-002490","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SynCardia TAH bridges patient for 119 days to successful heart transplant at UCSF Health","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Male patient in his twenties with biventricular heart failure received SynCardia TAH on Nov 15, 2025.","Device provided 119 days of circulatory support; successful heart transplant on March 14, 2026.","Second of five patients at UCSF Health successfully bridged to transplant using SynCardia TAH.","UCSF surgical director Amy Fiedler, MD, noted patient recovering well and praised partnership with SynCardia.","CEO Patrick Schnegelsberg cited growing adoption at leading transplant centers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112017,"accession_number":"0001829126-26-002346","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Patient supported 1,636 days on SynCardia Total Artificial Heart before transplant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["29-year-old patient implanted Sept 2, 2021 with SynCardia Total Artificial Heart.","Device sustained patient for 1,636 days (over 4 years) until successful heart transplant on Feb 24, 2026.","CEO highlights extended support capability while awaiting donor organ availability.","Over 2,100 SynCardia Total Artificial Heart implants performed worldwide; longest support exceeds 8 years.","Case informs clinical practice for long-term mechanical circulatory support in selected patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112016,"accession_number":"0001829126-26-002324","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Picard Medical shareholders authorize share increase to 330M and stock issuance for financing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting held March 10, 2026; 57.16% of 73.7M shares represented.","Proposal 1 passed: authorized shares increased from 180M to 330M (common from 150M to 300M), 41.7M for vs 395k against.","Proposal 2 passed: approval to issue >20% of outstanding shares to HT Investments MA LLC and High Trail Special Situations LLC, 41.7M for vs 320k against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112015,"accession_number":"0001829126-26-002256","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Picard Medical to feature SynCardia TAH on FOX Business BTV segment March 14","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Picard Medical (NYSE American: PMI) will appear on BTV Business Television on FOX Business on March 14, 2026 at 5:00 p.m. ET.","Segment highlights SynCardia Total Artificial Heart, with over 2,100 implants worldwide as a bridge to transplant.","Company also discusses development of a next-generation fully implantable artificial heart platform.","CEO Patrick N.J. Schnegelsberg noted raising awareness for advanced heart failure therapies is increasingly important."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112014,"accession_number":"0001829126-26-002250","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Picard Medical schedules Annual Business Update webcast for March 25, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Webcast will review FY and Q4 2025 financial results and provide a business update on commercial and strategic priorities.","CEO Patrick NJ Schnegelsberg, COO Matthew Schuster, and CFO Bernard Skaggs will present.","Clinicians Dr. Zain Khalpey and Dr. Amy Fiedler to discuss SynCardia Total Artificial Heart and Emperor platform.","Event includes a patient testimonial reflecting clinical experience with the device."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112013,"accession_number":"0001829126-26-001781","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Picard Medical to present preclinical Emperor TAH data and clinical outcomes at THT 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dr. Andre Simon to deliver three presentations at THT 2026 conference (Mar 2-4, Boston) on SynCardia TAH and Emperor system.","Preclinical data for next-gen fully implantable Emperor system shows preserved physiologic performance; aims to eliminate pneumatic drivelines.","Registry analyses show SynCardia TAH outcomes beyond survival: organ recovery, functional improvement, transplant eligibility preservation.","Educational lecture covers future TAH evolution: earlier intervention, organ recovery, transition to durable long-term support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112012,"accession_number":"0001829126-26-001652","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Picard Medical to host hands-on training with SynCardia Total Artificial Heart at THT 2026 conference","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Participates in inaugural Hands-On Training Day at Technology and Heart Failure Therapeutics 2026 in Boston on March 1, 2026.","Training led by clinical specialists; includes interactive stations with Companion 2 Driver, Freedom Portable Driver, and SynCardia Total Artificial Heart.","Quoting Stephen Zamojski: education and hands-on familiarity critical as adoption of total artificial heart therapy expands.","Event follows SynCardia Training Village in Houston; described as key component of commercial expansion strategy.","No financial details or guidance provided; announcement is a routine conference participation notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112011,"accession_number":"0001829126-26-000280","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Picard Medical launches podcast series on SynCardia heart and Emperor device","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Press release announces 'Cruxx to MedTech Podcast' exploring SynCardia Total Artificial Heart (STAH) and next-gen Emperor device.","Series features patient survival story and CEO Patrick NJ Schnegelsberg discussing STAH differentiation and commercial opportunity.","Podcast available on Apple, Spotify, Google Podcasts, and Cruxx website.","No financial results, guidance, or material operational changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112010,"accession_number":"0001829126-26-000265","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Picard Medical publishes investor presentation; expects FDA approval for fully implantable TAH by 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Over 2,100 STAH implants across 27 countries; only FDA-approved total artificial heart.","Mid-term catalysts: updated BTC label (2Q26), MDR CE-mark (4Q26), NMPA approval (4Q26).","Next-gen fully implantable TAH (Emperor) may seek FDA approval in 2028; patented.","U.S. reimbursement under DRG001 (mean ~$297k); market cap ~$123M as of Jan 11, 2026.","CEO Patrick Schnegelsberg leads team; stock traded $1.63-$13.68 since Aug 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128649,"accession_number":"0001829126-25-010336","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Picard Medical secures up to $50M senior secured notes; initial $15M funded at 0% interest, with warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $15M initial senior secured notes due Dec 26, 2028, at 0% annual interest, with option for up to $35M additional.","Warrants to purchase 7,009,346 shares at $2.675 per share, exercisable after 6-month lock-up or stockholder approval.","Net proceeds to be used for working capital and general corporate purposes; WestPark Capital acted as placement agent.","Notes are senior secured, collateralized by substantially all assets of Picard and IP of SynCardia subsidiary.","Company must maintain $4M cash minimum, seek stockholder approval for share issuance and authorized share increase to 300M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128648,"accession_number":"0001829126-25-010129","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Picard Medical rings NYSE Opening Bell on Dec 18, 2025, marking public company milestone","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["CEO Patrick NJ Schnegelsberg and management team to ring Opening Bell at NYSE on December 18, 2025.","Picard Medical, parent of SynCardia, highlights total artificial heart platform and FDA/Health Canada approvals.","Company touts more than 2,100 STAH implants across 27 countries and advancement of fully implantable Emperor system.","No financial results, guidance, or operational changes were disclosed in the press release.","Ceremonial event follows company's earlier listing on NYSE American under ticker PMI."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128647,"accession_number":"0001829126-25-009836","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Picard Medical announces patient lives over 8 years (2,900 days) with SynCardia Total Artificial Heart, a world record","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Patient at IVDK Dedinje Hospital (Belgrade, Serbia) reached 2,900 days on SynCardia Total Artificial Heart, longest ever recorded.","Five longest-term SynCardia patients globally are all from IVDK Dedinje Hospital, reflecting clinical excellence in Serbia.","Picard is developing the next-generation Emperor artificial heart system for broader long-term support access.","Patient received STAH on Dec 9, 2017 at age 46; now lives at home with family after 8 years of support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128646,"accession_number":"0001829126-25-009690","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Picard Medical presents Emperor TAH data showing hemodynamic equivalence to SynCardia STAH in vitro and in vivo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Emperor TAH uses identical blood-contacting materials as FDA-approved SynCardia STAH, replaces pneumatic driver with electromechanical system.","In vitro testing at 125 BPM demonstrates Frank-Starling autoregulation and afterload independence equivalent to pneumatic STAH.","First acute porcine implantation (3 models) separated from bypass without complications, delivering stable hemodynamic support.","Emperor TAH designed for full implantability with transcutaneous energy transfer and internal batteries, eliminating driveline.","SynCardia STAH has over 2,100 implants; Emperor aims to provide next-generation fully implantable TAH platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128645,"accession_number":"0001829126-25-009661","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Picard Medical CEO to present Emperor TAH data at CSI Focus D-HF in Frankfurt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Patrick NJ Schnegelsberg presenting on December 6, 2025 at 13:00 CET in the 'Durable Mechanical Circulatory Support' session.","Emperor Total Artificial Heart (TAH) is a fully implantable device; Picard's subsidiary SynCardia makes the first FDA/Health Canada-approved total artificial heart.","Conference runs December 5-6, 2025 in Frankfurt, Germany; no new financial or operational guidance disclosed in the release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128644,"accession_number":"0001829126-25-009479","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Picard Medical Secures $1M Bridge Loan from Chairman Affiliate at 6% Interest","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$1M unsecured promissory note issued to Fang Family Fund, LLC, an affiliate of Chairman Richard Fang.","Interest at 6% per annum, compounded annually; maturity November 27, 2026.","Proceeds for general corporate purposes, including working capital and liquidity management.","Mandatory prepayment if company raises $10M+ in equity financing; prepayable anytime without penalty.","Transaction approved by disinterested Audit Committee and Board as fair to the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128643,"accession_number":"0001829126-25-009457","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Picard Medical to present Emperor TAH in vitro data at ISMCS 2025 in Vienna","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Duffy Elmer to present benchtop performance data on the fully implantable Emperor Total Artificial Heart on Dec 4, 2025.","The Emperor TAH uses an internal motor-driven design eliminating the need for an external pneumatic driver.","Presentation at 31st Annual Meeting of the International Society for Mechanical Circulatory Support in Vienna.","Device aims to improve patient mobility and quality of life as next-gen SynCardia platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128642,"accession_number":"0001829126-25-009304","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SynCardia implants Emperor Total Artificial Heart in first in vivo study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three pre-clinical models successfully implanted with the Emperor TAH; all taken off bypass without issues.","Device provided full, stable blood circulation with efficient energy use and no technical problems.","Emperor TAH exhibited Frank-Starling response: natural pump output adjustment based on blood volume.","Results consistent with Picard Medical's laboratory performance goals; program acceleration expected.","Emperor platform designed as a fully implantable successor to the FDA-approved SynCardia TAH."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128641,"accession_number":"0001829126-25-009146","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Picard Medical Q3 revenue up 35% to $1.19M; IPO nets $15.5M in September","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.19M (+35% YoY); gross loss narrowed 81% to $0.13M; operating loss $3.36M vs $3.77M.","Net loss $22.7M includes $12.4M non-cash derivative revaluation charge upon IPO debt conversion.","IPO completed Sept 2: $19.5M gross proceeds ($15.5M net); retired convertible debt.","Appointed independent directors Sam Van and George Ye; patent granted for next-gen Emperor artificial heart.","Year-to-date revenue $3.93M (+11%); operating loss $10.3M; EPS ($0.96) vs ($1.79) prior."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":3931000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128640,"accession_number":"0001829126-25-008412","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Picard Medical issues statement on stock volatility, cites no undisclosed material change","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Picard Medical (NYSE American: PMI) states no undisclosed material change causing recent stock volatility.","Company remains focused on strategic and operational priorities; will comply with disclosure obligations.","Press release issued October 24, 2025 in response to intraday stock price fluctuation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128639,"accession_number":"0001829126-25-008062","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Stockholders approve amendment to 2021 equity incentive plan, increasing share reserve to 18M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment increases aggregate shares available to 18,000,000 from an unspecified prior limit; adds warrants as award type.","Vote results: 46,424,590 For, 7,727 Against, 7,945,013 Abstain; quorum of 54,377,330 shares represented.","Special meeting held October 10, 2025; record date September 16, 2025 with 73,701,176 shares outstanding.","Exhibit 10.1 filed with full text of Amended and Restated 2021 Equity Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145412,"accession_number":"0001829126-25-007290","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Picard Medical closes full over-allotment option in IPO, raising additional $2.55M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriters exercised option for 637,500 shares at $4.00/share on Sep 5, 2025.","Additional gross proceeds of ~$2.55M before expenses.","Total IPO now 4,887,500 shares with gross proceeds of ~$19.55M.","Shares trade on NYSE American under ticker PMI; WestPark Capital lead manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145411,"accession_number":"0001829126-25-007057","cik":2030617,"company_name":"Picard Medical, Inc.","ticker":"PMI","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["1.01","5.02","5.03","8.01","9.01"],"status":"ready","headline":"Picard Medical prices $17M IPO at $4/share; commences trading on NYSE American under PMI","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["4,250,000 shares sold at $4.00 for $17M gross proceeds; over-allotment option for 637,500 additional shares.","Proceeds to support China JV, R&D on fully implantable Emperor heart, and debt repayment.","Shares commenced trading on NYSE American on Aug 29, 2025 under ticker 'PMI'.","Underwriting Agreement with WestPark Capital as lead manager; firm commitment basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12536491.594500003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}